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Polymeric nanogels find a relevant field of application in the formulation of a new generation of therapeutic and preventive vaccines,
aiming at the fine-tuned modulation of the immune response. Intrinsic properties of polymeric nanogels, such as material chemistry, size and
shape, surface charge, and hydrophobicity or hydrophilicity, may be determining factors in shaping the induced immune response. These
materials can thus work as synthetic adjuvants, which can also be conjugated with immunostimulants. Polymeric nanogels protect vaccine
antigens from degradation in vivo and, surface-conjugated with antibodies or specific ligands, could increase active targeting specificity. This
review covers the recent published data concerning the modulation of innate and adaptive immune responses by engineered polymeric
nanogels and their potential application as delivery systems in vaccination.
From the Clinical Editor: In this review, the utility of polymeric nanogels is discussed as adjuvants and protective agents for enhanced
vaccination with more robust immune response and a more uniform outcome.
© 2013 Elsevier Inc. All rights reserved.
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principle of vaccination. Usually, immunogenicity depends on the
action of antigen-presenting cells (APCs), into which antigens
must be carried to be internally processed for surface presentation
to T cells. In addition to antigen presentation, APC-dependent
activation of the T cells also requires the upregulated expression of
surface co-stimulatory molecules or secreted factors such as
cytokines (Figure 1). Cytokines released from APCs drive the
differentiation of T cells, which acquire effector functions
including antigen-speciﬁc cytotoxicity or speciﬁc help to cellular
or humoral immunity. In naturally occurring immunizations,
especially in the course of infection, the upregulated expression of
T-cell co-stimulatory molecules or cytokines by APCs is triggered
by ligands characteristic of invading pathogens, generally
designated as pathogen-associated molecular patterns. These
may be recognized by speciﬁc pattern-recognition receptors on
the surface, in the cytosol, or inside intracellular compartments, of
which Toll-like receptors (TLRs) are the prototypical example.1S.A. Ferreira is the recipient of a fellowship from International Iberian
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subunit vaccine formulations, adjuvants might be necessary to
potentiate such mechanisms of T-cell stimulation and therefore
immunogenicity. Some adjuvants can act on APCs by engaging
speciﬁc pattern-recognition receptors, thus mimicking signals
usually provided by pathogens.2 In addition, some delivery
systems (e.g., liposomes or virus-like particle preparations) can
combine adjuvant activity with the targeted delivery of antigens to
APCs.3 Only a few adjuvants are currently licensed for human
vaccines, which include alum (aluminum salts), MF59, Adjuvant
System 03 (AS03), Montanide ISA 51, Adjuvant System 04
(AS04), and virosomes.2,4,5 Approved adjuvants are mostly used
in preventive vaccines for diseases caused by viruses or
extracellular bacteria, for which speciﬁc antibodies provide
signiﬁcant protection.5 This illustrates one of the limitations of
current vaccines: their efﬁcacy mostly relies on the induction of
protective antibodies rather than on cell-mediated immunity.6 This
may hamper the immune-based prevention of diseases caused by
intracellular pathogens or cancer, where cellular immunity is a key
effector mechanism.7 To overcome the limitation mentioned and
to improve vaccine performance or potency as well, novel
compounds or formulations are currently being rationally
designed. Among them, polymeric nanogels have potential to be
safe and effective alternatives to the current means of vaccine
delivery, being able to induce not only strong and long-lastingnogels as vaccine delivery systems. Nanomedicine: NBM 2013;9:159-173,
Figure 1. Vaccination antigens (Ag), e.g., puriﬁed proteins, may be internalized by antigen-presenting cells (APCs) from the external milieu by phagocytosis or
other endocytic processes (1). Within endocytic compartments (EC), antigen is processed at acidic pH into peptide fragments (pt) (2). Peptides are then loaded to
major histocompatibility complex (MHC) class II molecules (MHC II) transported in vesicles originating from Golgi apparatus (Golgi) into endocytic
compartments (3). Mature endosomes fuse with the plasma membrane where peptides loaded to MHC class II molecules are exposed. Antigens may also be
delivered to the cytosol and cleaved within the proteasome (Prt), resulting in peptides (4). These are transported into the endoplasmic reticulum (ER), where they
are loaded to MHC class I molecules (MHC I) in a chaperone-assisted process (5). Peptide-loaded MHC class I molecules are transported to the cell membrane
(6), where they can be recognized by speciﬁc CD8+ T cells, whereas CD4+ T cells recognize peptides presented in the context of MHC class II molecules (7).
APCs also provide co-stimulatory stimuli by either surface molecules (8) or soluble factors such as cytokines (9).
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on CD4+ and CD8+ T-cell responses. Polymeric nanogels may
combine immunomodulatory properties with targeted antigen
delivery features, working as integrated adjuvants.8,9
Polymeric nanogels as vaccine delivery or adjuvant systems
Nanometer-sized polymeric hydrogels—nanogels or hydro-
gel nanoparticles (NPs; size from 1 to 1000 nm)—are swollen
networks composed of amphiphilic or hydrophilic polyionic
polymers, either natural or synthetic. Nanogels are promising
multifunctional polymeric NPs with potential as delivery
systems because of their unique properties. These include
tunable chemical and physical structures, ﬂexible nanosize,
large surface area for multivalent conjugation, high water
content, biocompatibility,10,11 loading capacity, stability, ability
to target speciﬁc cells and speciﬁc cell compartments, immuno-
modulatory properties, and responsiveness to environmental
factors.12 As nanocarriers must be delivered to speciﬁc sites
upon injection into body ﬂuids, the possibility of modulating the
chemical and physical properties of NPs could be most helpful in
overcoming major biological barriers such as the reticuloendo-
thelial system, clearance through kidney glomeruli, and
nonspeciﬁc accumulation in different organs.
Nanogels have been designed using different approaches,
which can be classiﬁed into physical self-assembly of interactive
polymers, polymerization of monomers in a homogeneous phase
or in a micro or nanoscale heterogeneous environment, cross-
linking of preformed polymers, and template-assisted
nanofabrication.13 Several natural biopolymers have beencommonly used to develop nanogels, for example, dextran,
dextrin, pullulan, mannan, chitosan, poly-L-lysine, poly(γ-
glutamic acid) (γ-PGA), heparin, hyaluronic acid, and alginate.
Synthetic biodegradable and biocompatible polymers—for
example, poly(methyl methacrylate) (PMMA), poly(D,L-lactic
acid) (PLA), poly(glycolic acid) (PGA), poly(D,L-lactic-co-
glycolic acid) (PLGA), and poly(ε-caprolactone) (PCL)—
approved for human administration by the US Food and Drug
Administration,14 have frequently been used in the development
of potential vaccine delivery systems.
NPs may be engineered so as to either stimulate or suppress
the triggered immune response, thus providing the appropriate
activity: upregulation or downregulation of the immune
response, respectively, in the prevention or treatment of
infections and cancer or of allergies and autoimmune diseases.15
A compilation of studies in which different NPs have been used
as delivery systems for antigens or nucleic acids in different
experimental or clinical settings is presented in Table 1. The
interaction of particulate delivery systems with APCs may
stimulate these cells in a way resembling the stimulation
triggered by pathogens, which are commonly recognized,
phagocytosed, and processed by professional APCs. In vitro
studies have shown that exposing dendritic cells (DCs) to
polymeric NPs resulted in their activation and maturation, as
evidenced by upregulated surface expression of major histo-
compatibility complex (MHC) class II or co-stimulatory
molecules (CD40, CD80, CD83, and CD86),29,33,68 secretion
of cytokines65 and chemokines, and expression of chemokine
receptors.72 Activated DCs migrate to regional lymph nodes,
where they present antigen to T cells, thereby triggering cellular
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The intrinsic adjuvant properties of NPs to stimulate APCs may
thus be an additional advantage in their potential as antigen
delivery systems for vaccination. In vaccination, the relationship
between the rate of antigen availability and the induction of the
immune response is poorly understood as, apparently, no clear or
direct correlation could be found between in vitro antigen release
proﬁle and the antigen-speciﬁc in vivo immune response.
Indeed, both rapid and extended in vitro antigen release proﬁles
have been shown to induce similar immune responses in animal
studies upon intranasal administration.39,73 Continuous antigen
delivery is usually considered to be more effective in inducing
immunity, as prolonged antigen exposure allows enough time for
afﬁnity maturation and antibody isotype switching to occur, and
immune memory to be generated.74 Moreover, in a DNA-based
vaccine delivery system, controlled release of DNA in synchrony
with the natural development of the immune response seems to
be crucial for the efﬁcacy of the vaccine.75 However, it has been
suggested that antigen presentation by APCs to naive and
effector T cells may be required over only the ﬁrst few days for
an efﬁcient induction of T-cell expansion and differentiation, and
that antigen presentation for weeks or months may instead lead to
T-cell death, decreased effector expansion, and reduced cytokine
production by recovered effectors.76Properties of the nanodevice vs. immune response
Nanogels themselves may be intrinsically immunologically
active, by virtue of their particular character or as a result of
protein adsorption, being recognized as a “danger signal.”
Properties of the nanodelivery systems, such as material
chemistry, size and shape, surface charge, and hydrophobicity
or hydrophilicity, are determining factors in the induced
immunity and will be discussed below.
Material chemistry
The molecular weight and the co-polymer composition can
modulate the load release mechanism; higher polymer molecular
weight results in slower in vitro release of the biological agent.77
On the other hand, the functional groups at the nanogel surface can
be modiﬁed with various targeting moieties for site-speciﬁc
vaccine delivery. A number of materials chemistries have been
engineered to promote release of NPs' payload within the
endolysosomal compartments, attending to both pH and the
reductive-oxidative gradient experienced during endolysosomal
processing.78 Nanomaterials sensitive to acid hydrolysis (orthoe-
sters; hydrazide or acetal bonds)69,70,79 or to reduction (glutathi-
one-responsive)80 have been investigated for endosomal release of
biological agents. Whereas the endosomal-phagosomal compart-
ment is the aimed target for MHC class II loading, MHC class I
presentation requires that the antigen payload be present in the
cytosol.81 Thus, disruption of the endosomal membrane barrier so
that exogenous antigens could gain access to the cytosol is an
important target and a challenging problem. Endosomal disruption
is also necessary for DNA-based vaccination, in which plasmid
DNA must be expressed to produce the antigen.82 To avoid
lysosomal trafﬁcking, “smart” polymers have been designed. BothpH-sensitive and reductive-sensitive nanomaterials release oligo-
nucleotides and peptides into the cytosol as the endosome is
acidiﬁed, avoiding the lysosomal fusion. As a consequence,
antigen processing may occur through the cytosolic (MHC class I)
pathway instead of the exogenous (MHC class II) pathway, thus
promoting cross-presentation. Indeed, endosomal escape follow-
ing uptake of PLGANPs loadedwith ovalbumin (OVA) have been
linked to an increase in the presence of antigen in the cytosol and
promoted cross-presentation, enhancing and sustaining antigen
presentation via MHC class I to a much higher degree than soluble
antigen, in murine bone marrow–derived DCs.83 Protamine-
coated PLGA NPs stimulated murine bone marrow–derived DCs
and enhanced the cross-presentation of encapsulated exogenous
antigen (OVA) by facilitating antigen uptake and lysosomal
escape.84 Moreover, HIV envelope glycoprotein (gp)120 loaded
in hydrophobically modiﬁed γ-PGA (γ-hPGA, γ-PGA-graft-L-
phenylalanine co-polymers) NPs induced antigen-speciﬁc effec-
tor and CD8+ T-cell memory response in intranasally (IN)
immunized mice.46 Acid-degradable particles, whose compo-
nents exert an osmotic pressure on the endosomal-phagosomal
membrane, leading to its rupture, have been used to enhance
antigen presentation in vitro and vaccination in vivo.68,85,86
CD205 (dendritic and epithelial cells, 205-kDa integral
membrane glycoprotein, or DEC-205)-targeted acid-degradable
acetal–cross-linked OVA-loaded particles enhanced antigen
presentation by DCs via both MHC class I and II pathways,
leading to an improved cellular immune response.85 Co-delivery
with adjuvants [unmethylated cytosine-phosphate-guanine
(CpG) and interleukin-10–speciﬁc antisense oligonucleotides]
increased secretion of interleukin (IL)-12 and maximized the
elicited cellular immune response.86 Acid-degradable acetal–
cross-linked NPs encapsulating both OVA and CpG (TLR9
agonist) induced an OVA-speciﬁc CD8+ T-cell response.68 The
same system, but with CpG covalently attached, enhanced the
efﬁcacy of antigen presentation via MHC class I, leading to a
greater cytotoxic T-cell activity, as compared with particles
subcutaneously (SC) co-administered with adjuvant in an
unbound form in mice.70 This system effectively induced
protective immunity using the MO5 murine melanoma model
until the moment when the cancer cells apparently stopped
expressing the antigen, due to in vivo selection pressure.70
Immune potentiation can also be achieved by activating the
complement system. Triggering of complement activates a series
of proteins and enzymes that can promote inﬂammation,
macrophage phagocytosis, anaphylaxis, B-cell activation, and
T-cell response, as well as enhance antigen presentation to B
cells by follicular DCs.9 Certain primary hydroxyls87 or amine
groups88 on the pathogen molecules or on the material surface
can bind to the exposed thioester of C3b to activate complement
by an alternative pathway.87,89 Furthermore, activating materials
also facilitate the binding of factor B to C3b, forming the C3
convertase, which catalyzes the cleavage of more C3, thus
amplifying the response.89 Interestingly, C1q binds to hydro-
phobic molecules or aggregates, such as lipopolysaccharide
(LPS) and liposomes.90 Hence, the incorporation of hydrophobic
domains could activate complement through the classical
pathway. In summary, although much of biomaterials research
seeks to avoid interactions with the complement system,
Table 1
Polymeric nanogels as delivery systems for antigens or nucleic acids
Polymeric nanogels† Antigen or nucleic acid Model‡ Response Route(s) Reference
CHP HER2 Human IgG, CD4+, CD8+ T cells SC 16-18
CHP NY-ESO-1 Human IgG, CD4+, CD8+ T cells SC 18-20
Chitosan–deoxycholic acid MAGE-3 peptide 615 mice IFN-γ, cytotoxic T cells SC 21
Chitosan TT BALB/c IgG, IgA IN 22
Chitosan TT BALB/c IFN-γ, IgG IN 23
Chitosan HBsAg BALB/c IgG IM/IN 24
Chitosan-alginate (+ CpG) HBsAg BALB/c IgG, IgA IN 25
Chitosan Leishmania superoxide
dismutase
BALB/c IgG SC 26
Chitosan Plasmid DNA encoding
peanut allergen
AKR/J mice Decreased IgE Orally 27
Chitosan Plasmid DNA encoding HBsAg BALB/c IFN-γ, IL-2, IgG, IgA IN 28





Chitosan Plasmid DNA encoding VP1
of CVB3
BALB/c IgG, IgA, cytotoxic T cell IN 30
Chitosan Plasmid DNA encoding
RSV antigens
BALB/c IFN-γ, IgG, IgA,
cytotoxic T cells
IN 31
Chitosan/TMC OVA BALB/c IgG intraduodenally 32
TMC OVA BALB/c IgG ID 33
TMC OVA BALB/c IgG IM 34,35
TMC OVA BALB/c IgG, IgA IN 35
TMC (+ LPS/CTB/
PAM3CSK4/MDP/CpG)
OVA BALB/c IgG, IgA ID/IN 36
TMC–hyaluronic acid OVA BALB/c IgG IN/ID 37
TMC HBsAg BALB/c IgG/IgA IN 38
TMC DT BALB/c IgG ID 33
TMC Inﬂuenza A subunit H3N2 C57BL/6 IgG/IgA IM/IN 39
TMC-MCC TT BALB/c IgG IN 40
TMC-alginate Urease Kunming mice IgG/IgA SC/oral 41
γ-hPGA Listeriolysin peptide C57BL/6 Survival Rear footpad 42
γ-hPGA Tax peptide C3H mice Cytotoxic T cells SC 43
γ-hPGA gp100 peptide C57BL/6 IFN-γ SC 43
γ-hPGA EphA2 peptide C57BL/6 IFN-γ, cytotoxic T cells IP 44
γ-hPGA OVA C57BL/6 Cytotoxic T cells SC 45
γ-hPGA OVA C57BL/6 IgG, cytotoxic T cells Rear footpad 42
γ-hPGA HIV-1 gp120 BALB/c IFN-γ, cytotoxic T cells IN 46
γ-hPGA HIV-1 p24 BALB/c IFN-γ, IgG SC 47
γ-hPGA Inﬂuenza HA BALB/c IFN-γ, IL-4, IL-6, IgG,
cytotoxic T cells
SC 48
γ-hPGA Inﬂuenza HA BALB/c IFN-γ, IL-4, IL-6, IgG/IgA SC/IN 49
PEI/γ-PGA Plasmid DNA encoding P. yoelii
MSP-1 C-terminal
C57BL/6 IFN-γ, IL12p40, IgG IV 50,51
PLA (+ poly-U) OVA C57BL/6 IFN-γ, IgG SC 52
PLA HIV-1 p24 and/or gp120 BALB/c IL-2, IL-6, IL-10, IgG,
cytotoxic T cells
SC 53,54
PLA HBsAg Wistar rats IFN-γ, IgG IM 55
PLGA Allergen Bet v 1 BALB/c IFN-γ, IL-10, decreased IgG1 SC 56
PLGA (+ 7-acyl lipid A) TRP-2 peptide C57BL/6 CD8+-derived IFN-γ SC 57
PLGA, PLGA/TMC OVA BALB/c IgG IM 35
PLGA (+ 7-acyl lipid A) OVA BALB/c IFN-γ, CD4+, CD8+ T cells IP/SC 58
PLGA (+ MPL) OVA BALB/c IgG, IgA Orally 59
PLGA (+ CpG) TT C57BL/6 IFN-γ, IgG SC 60
PLGA B. pertussis toxoid and
ﬁlamentous HA
BALB/c IFN-γ, IL-5, IgG IP/orally 61
PLGA BSA BALB/c IgG SC/orally/IN 62
PLGA Protein from N. meningitides
type B
CD1 mice IgG IM/IP 63
PLGA (+ LTK63) HIV-1 gp140 BALB/c IgG IN + IM 63
PLGA (+ MPL) HBcAg C57BL/6 IFN-γ SC 64
PLGA-PEI Rv1733c DNA /protein BALB/c IFN-γ IM/pulmonary 65
PCL, PLGA, PLGA-PCL DT BALB/c IFN-γ, IL-6, IgG IN/IM 66
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Table 1 (continued)
Polymeric nanogels† Antigen or nucleic acid Model‡ Response Route(s) Reference
PCL-based (+ CTB) S. equi proteins BALB/c IL-2, IL-4, IgG IN 67
Acid-degradable
polyacrylamide (+ CpG)
OVA C57BL/6 Cytotoxic T cells SC 68-70
PMMA–Eudragit L100-55 HIV-1 Tat protein BALB/c IFN-γ, IL-4, IgG,
cytotoxic T cells
IN 71
BSA, bovine serum albumin; CHP, cholesterol-bearing pullulan; CpG, cytosine-phosphate-guanine; CTB, cholera toxin B subunit; DT, diphtheria toxoid; EphA2,
ephrin type-A receptor 2; γ-hPGA, hydrophobically modiﬁed poly-(γ-glutamic acid), γ-PGA-graft-L-phenylalanine co-polymers; HA, hemagglutinin; HBcAg,
hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HER2, human epidermal growth factor receptor 2; ID, intradermally; IFN-γ, interferon-γ; Ig,
immunoglobulin; IL, interleukin; IM, intramuscularly; IN, intranasally; IP, intraperitoneally; IV, intravenously; LPS, lipopolysaccharide; MAGE-3, melanoma-
associated antigen 3; MCC, mono-N-carboxymethyl chitosan; MDP, muramyl dipeptide; MPL, monophosphoryl lipid A; MSP-1, merozoite surface protein 1; NY-
ESO-1, New York-esophagus 1 protein; OVA, ovalbumin; PAM3CSK4, Pam3Cys-Ser-(Lys)4; PCL, poly(ε-caprolactone); PEI, poly(ethylenimine); γ-PGA,
poly-(γ-glutamic acid); PLA, poly(D,L-lactic acid); PLGA, poly(D,L-lactic-co-glycolic acid); PMMA, poly(methyl methacrylate); poly-U, poly(uridylic acid); SC,
subcutaneously; RSV, respiratory syncytial virus; TMC, N-trimethyl chitosan; TRP-2, tyrosinase-related protein-2; TT, tetanus toxoid.
† Immunostimulants (if used) are shown in italics within parentheses.
‡ BALB/c and C57BL/6 are mice strains unless otherwise indicated.
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ment activation and could affect innate and adaptive immunity in
diverse ways.
Size and shape
The size of the polymeric particulate vaccine delivery systems
and their interactions with APCs inﬂuence the immune response
both qualitatively and quantitatively.13 The nanoscale size is
advantageous in vaccine delivery, improving the safety, stability,
and targeted delivery of biological agents, enhancing the
transport across biological barriers and hence the bioavailability,
extending the effect in the target tissue.12
Particle size is the critical factor for lymphatic uptake from the
interstitial space.91 Therefore, particles N100 nm frequently
remain near the administration site and are internalized by
immature peripheral DCs that then migrate to lymph nodes,
mature, and present antigen to T cells. Particles b50 nm in
diameter are more efﬁciently carried into lymphatic vessels by
the interstitial ﬂow and transported to regional draining lymph
nodes, where concentrated populations of resident immature
DCs internalize them.87,92,93 Therefore, the size of particles is a
determinant for their applicability toward targeting peripheral vs.
lymph node DCs. Interestingly, size may also affect internali-
zation of targeted biomaterials by APCs. DCs have been
described to internalize PLGA-based DC-SIGN-targeted NPs
and microparticles (MPs; size from 1 to 1000 μm) more
effectively than nontargeted controls. However, NPs were more
effectively targeted than MPs, as demonstrated by the relatively
high nonspeciﬁc uptake of MPs by DCs. Contrastingly,
scavenging by other phagocytes occurred more efﬁciently for
targeted MPs rather than for NPs.94
Transport across mucosal surfaces may also be affected by
particle size. Mucosae are both an appealing and challenging
route for vaccination. NPs must gain access to the mucosal
epithelia for antigen delivery or transfection. Therefore, they
must be able to penetrate the mucous layer. The mucus consists
of a physically cross-linked, viscoelastic hydrogel, with mesh
sizes in the order of 10–100 nm.95 Barrier penetration has been
shown largely restricted for particles greater in diameter than a
few hundred nanometers,95,96 whereas particles of about 50 nm
could diffuse in mucus almost as freely as in water.95 NPs havebeen described to improve transmucosal transport and transcy-
tosis by microfold (M) cells.41 Indeed, NPs crossed the mucosal
epithelium better than MPs, in that not only M cells overlying the
mucosa-associated lymphoid tissues but also the epithelial cells
were involved in the transport of NPs.73 A better uptake by
Peyer's patches was observed for negatively charged PLGA
particles having a mean diameter of ≤1 μm.97
Nanomaterial size may also determine its immunological
activity, by inﬂuencing uptake by APCs and their maturation.98
Indeed, it has been shown that cell uptake of NPs was relatively
high, when compared to that of MPs.99,100 The NPs' size-
dependent immunomodulation is a key feature in their potential
use in vaccination. Immunization with PLA NPs entrapping
hepatitis B surface antigen (HBsAg) has been previously linked
with higher levels of interferon (IFN)-γ production and with
antibody isotypes associated with T helper (Th)1-type immune
response. Conversely, immunization with MPs promoted IL-4
secretion and favored Th2-type immune response.
55 However,
immunization with PLGA MPs loaded with Bordetella pertussis
antigens elicited a marked Th1 immune response, whereas
similarly loaded NPs favored a Th2 immune response.
61 In
another model, synthetic peptide malaria vaccine SPf66-loaded
PLGA NPs proved to be poorly immunogenic, while SPf66-
loaded MPs elicited potent, long-lasting systemic antibody levels
and mixed Th1/Th2 immune response in IN-immunized mice.
101
Therefore, the type of size-dependent polarization of the immune
response may also depend or be affected by the particular antigen
loaded or other NP characteristics.
In addition to its type, the intensity of the humoral immune
response seems to be also affected by particle size, as signiﬁcant
variations on antibody titers were observed after a single
immunization, using differently sized PLA particles entrapping
HBsAg.55 NPs have been shown to be efﬁciently taken up by
macrophages but elicited lower antibody titers in comparison to
MPs. PLA MPs eliciting the highest and long-lasting antibody
titers after single immunization were found attached to the
macrophage cell surface, not being internalized.55 Bovine serum
albumin–loaded PGLA particles (1 μm) induced a higher
humoral response, immunoglobulin (Ig)G-mediated, than smal-
ler particles administered by oral and intranasal routes.62 Other
studies did not reveal the same size-dependent effect. PLGA NPs
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antigen from Neisseria meningitidis type B [intramuscularly
(IM) or intraperitoneally (IP)], and a HIV-1 envelope gp140 (IN
followed by an IM boost) elicited comparable immune response
in mice.63
Although it is not obvious how one speciﬁc size range could
be optimal for particular vaccine formulations, it is however clear
that controlling the size of a vaccine particle could be a means to
bias the immune response.102,103
The particle geometry has been described as a strategic
feature regarding transport through the vasculature, circulation
half-life, targeting efﬁciency, endocytosis, and subsequent
intracellular transport.104,105 Spherical and cylindrical particles
have been described to be phagocytosed more effectively than
ellipsoid or disk-shaped particles. Elongated particles have been
reported to avoid phagocytosis and remained in circulation for
longer times, whereas both elongated and ﬂat particles targeted
the disease site better than their spherical counterparts.104
Surface charge
Surface charge may affect bioadhesivity, entrapment efﬁ-
ciency, percent loading, stability, and in vivo immunogenic
performance of a vaccine formulation.106 As a result of the
supercoiled structure and negative charge, the entrapment
efﬁciency and stability of DNA-based vaccine formulations is
usually low. Cationic nanomaterials form complexes with
plasmid DNA by electrostatic interactions, increasing stability
and entrapment efﬁciency.30,107 A net positive surface charge
can facilitate transfection by favoring the interaction with the
negatively charged glycoproteins at the cell membrane. Howev-
er, electrostatic interactions with solutes or proteins from blood
and interstitial ﬂuid can lead to competitive binding, destabili-
zation of the carrier, and subsequent premature release of the
nucleic acid payload.82 These cationic delivery systems have
been shown to enhance mucosal and systemic immunogenicity,
including the generation of efﬁcient mucosal antibody response
and cytotoxic T cells after intranasal administration,31 hence
providing an attractive alternative to parenteral administration. It
is therefore critical to control the cationic charge density to
minimize the toxicity frequently associated with polycationic
materials such as poly(ethylenimine) (PEI), while attaining high
immune response.
The electrostatic interactions between the mucus—an anionic
polyelectrolyte—and the cationic NPs, resulting in mucoadhe-
sion, may provide sufﬁcient residence time for an efﬁcient
antigen uptake. Mucoadhesive, hydrophilic NPs have received
much attention to deliver protein antigens via the nasal
route.22,73,108,109 Mucoadhesive NPs improve mucosal absorp-
tion, because they strongly attach to the mucosa and increase the
viscosity of mucin. Thereby, they signiﬁcantly decrease the nasal
mucociliary clearance rate and thus increase the residence time of
the formulation in the nasal cavity. For instance, carriers of
chitosan and derivatives—polyampholyte mono-N-carboxy-
methyl chitosan (MCC) and positively charged N-trimethyl
chitosan (TMC) loading tetanus toxoid (TT)—enhanced muco-
sal immune response in IN-immunized mice.108 MCC induced
relatively lower IgG titers for TT when compared with TMC and
chitosan, yet producing the smallest NPs, with narrower sizedistribution and higher loading capacity.108 TT-loaded TMC-
MCC NPs, obtained without using any organic solvent or cross-
linker, induced both mucosal and systemic immune responses in
IN-immunized mice.40
Hydrophobicity and hydrophilicity
Certain material features can mimic pathogen surfaces
leading to the activation of innate immune pathways. Some
biomaterials, particularly polymers that contain hydrophobic
domains, exhibit natural adjuvant behavior. A positive correla-
tion was observed between hydrophobicity of diphtheria toxoid–
loaded PLGA, PCL, and PLGA-PCL NPs, their in vitro uptake,
and the serum levels of antigen-speciﬁc IgG achieved in IN-
immunized mice.66 The mechanism(s) by which biomaterials
hydrophobicity affects the inﬂammatory and antibody responses,
although not fully elucidated, may involve the complement
system, TLRs, or both. TLR4 binds to a variety of structurally
dissimilar ligands, many of them (including LPS and bacterial
ﬁmbriae) having hydrophobic domains. The hydrophobic
domains of these ligands might be sensed as a “danger signal”
by TLRs to initiate innate immune response.110 Similarly,
hydrophobic portions of polymers in vehicles might interact
speciﬁcally with TLRs and induce DC maturation and adaptive
immunity.90 For example, LPS-free γ-hPGA NPs stimulated
DCs through TLR2 and TLR4, possibly through the hydropho-
bic regions.72 This was reached through MyD88-mediated
nuclear factor–kappa B activation and p38 mitogen-activated
protein kinase pathways, in a manner somewhat similar to LPS
signaling through TLR4.42,72,111,112
Once exposed to a biological environment, hydrophobic
material surfaces are obscured by protein adsorption faster than
the hydrophilic ones,82 affecting the phagocytosis and clearance
by macrophages (e.g., through scavenger receptors) and hence
potentially affecting distribution and delivery to the intended
target sites.113 Immunoglobulins, complement components, or
other opsonins adsorption might be advantageous to induce
immunity.113 A study with DC-SIGN-targeted PLGA NPs,
coated with hydrophilic poly(ethylene glycol) (PEG) of various
chain lengths to shield nonspeciﬁc interactions, demonstrated
that PEG chains cannot be extended beyond a certain length
without compromising the efﬁcacy of targeted delivery.114 The
addition of PEG and other hydrophilic polymers can also result
in lower transfection efﬁciency.82
A hydrophilic surface—for example PEG, poly(ethylene
oxide), Pluronic, or poloxamers—is relevant to withstand
aggregation and adsorption of particles to components of the
mucus and permit their transport as individual particles. Shorter,
denser graft layers of PEG tend to sterically stabilize the NPs
surface, whereas longer, sparser grafts allow interpenetration of
the grafted chains and the mucous network, leading to adhesion
to the mucus, associated with entanglement and disentangle-
ment, and unfavorable slower NPs penetration.115 Therefore,
PEG chains long enough (2 kDa)96 to prevent adsorption, but
not long enough (10 kDa)115 to lead to entanglement, are
desirable. PEG coating of PGLA NPs has been shown to
enhance diffusion in human cervical mucus in a manner strongly
dependent on PEG molecular weight and density116; in PLA
NPs, PEG coating has favored penetration across rat nasal
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character of the transmucosal nanocarriers is controversial in
different reports and remains a dilemma.117
Multifunctional vaccine delivery systems
A range of technologies and approaches have been used for the
development of nanosized vaccine delivery systems, aiming at
improving preventive and therapeutic vaccination methods.77
They are designed to protect antigen from enzymatic
degradation,12,29,118 to extend antigen release,74 to closely
mimic the size, shape, surface molecular organization,119
composition, and immunological processing of actual pathogens;
to actively or passively target APCs for efﬁcient delivery120;
direct the nature of the resulting immune response, and ﬁnally, to
induce APCs maturation by interacting with elements of the
innate immune system, such as TLRs.102,119 Polymeric vehicles
also offer the signiﬁcant beneﬁt of reducing the toxicity due to
inﬂammatory cytokines often observed after injection, a common
side effect of immunostimulants, by directly targeting APCs.121
Vaccines may include synthetic peptides representing an
epitope of a pathogen protein; a full-length protein carrying
several epitopes that may be recognizable by B and T cells,
produced either by pathogens, synthetically or recombinantly; or
a gene encoding a particular protein fused into a DNA or RNA
plasmid. These vaccines offer considerable advantages over
traditional empirical vaccines, based in live-attenuated, inacti-
vated, or killed pathogens, in terms of safety, stability, and
production cost. However, in most cases subunit vaccines have
limited immunogenicity and require the addition of adjuvants to
induce a protective and long-lasting effective immune
response.86,102 Antigens in subunit vaccines are taken up by
DCs but usually lack the necessary “danger signals” to induce
DC maturation. Several immunostimulants may therefore be co-
administered either by co-injection or by physical linkage to the
carrier via surface adsorption and co-encapsulation.36,60,122 An
antigen–adjuvant mixture stimulates the activation of immature
DCs, but an antigen–adjuvant conjugate increases the chance of
simultaneous uptake of both adjuvant and antigen to the same
endocytic compartment, resulting in higher numbers of mature
antigen-carrying DCs,34 which are necessary to ensure optimal
antigen presentation to CD4+ T cells, cross-presentation and
induction of CD8+ T-cell response,123 and increased humoral
immune response.34,52
Adjuvants are molecules, compounds, or macromolecular
complexes that evoke or enhance the potency and longevity of a
speciﬁc immune response against co-inoculated antigens.4,6,77
The adjuvants chosen should meet several criteria, including
target site, antigens, type of desired immune response, route of
administration, animal species to be vaccinated, duration of
immunity, prevention of adverse effects, and stability of the
vaccine.4,124 An optimally formulated adjuvant must be able to
promote an antigen-speciﬁc immune response and should be
safe, intrinsically nonimmunogenic, biocompatible, readily
biodegraded and eliminated, inexpensive to produce, stable
before administration, and physicochemically well deﬁned to
facilitate quality control important to ensure reproducible
manufacturing and activity.4,6Multivalent vaccines that encapsulate not only a combina-
tion of multiple antigens31,67 (necessary in many diseases
associated with multiantigenic variability and shedding), but
that also combine the synergy between different adjuvant
mechanisms25,36 using mixtures of immunostimulants and
delivery systems, have been under preclinical study.
Peptide-based vaccines
Peptide epitopes might be recognized by antibody or immune
cells. Synthetic peptide-based immunogens are easily produced,
are free of bacterial or viral contaminating substances, are devoid
of oncogenic potential, present low adverse reactions, have low
cross-reactivity and high stability, but also have poor inherent
immunogenicity.77 Peptide-based vaccines can include several
peptide epitopes corresponding to subtypes of a pathogen,
different stages in the life cycle of a pathogen, or even epitopes
from multiple pathogens.125
To overcome the limitations of using single cytotoxic T-cell
epitopes imposed by MHC polymorphism, mixtures of separate
peptides or polytope vaccines have been designed by producing
recombinant proteins consisting of a combination of Th and/or
cytotoxic T-cell epitopes. Physical linking of Th and cytotoxic T-cell
peptide epitopes further increased the magnitude of the cytotoxic
T-cell response, suggesting that presentation of both Th and
cytotoxic T-cell peptide epitopes on a single APC is more efﬁcient
than when the two epitopes are presented on different APCs, which
may occur when these epitopes are delivered as a mixture.126,127
Peptide-based vaccine efﬁcacy is determined by how the
peptides are recognized by the immune system. Speciﬁc immune
response can be signiﬁcantly affected by the presence of Th
epitopes, peptide concentration, multivalency, secondary
structure,102 geometry,128,129 orientation (N terminus or C
terminus of B-cell epitopes could determine antibody speciﬁcity),
chemical linkage between separately synthesized peptide
modules,127 association with adjuvants (self-adjuvanting lipo-
peptides, such as tripalmitoyl-S-glyceryl cysteine coupled to
appropriate synthetic epitopes), and size. Long synthetic peptides
are not able to bind directly toMHC class I or II molecules and are
therefore taken up, processed, and presented by APCs.102
The induction of robust CD8+ T-cell response requires a
sustained presentation of antigen in a stimulatory context. Carrier-
induced epitope suppression and in vivo biodegradation should be
avoided. Biodegradation escape can be achieved by using non-
natural “protease-resistant” derivatives of cytotoxic T-cell epitopes
that still retain the antigenicity and immunogenicity of the parental
peptide, or by using a high number of repetitive injections with
minimal cytotoxic T-cell peptide epitopes within a week and for
several courses.126 Although vaccines of small peptides can be
rapidly biodegraded, larger peptides are relatively protected and
may actually beneﬁt from additional extracellular processing.126
Some examples of polymeric nanogels tested as potential
peptide-based vaccine delivery systems with chitosan, γ-PGA,
and PLGA are summarized below.
Chitosan
Chitosan-conjugated deoxycholic acid NPs, self-assembled
with melanoma-associated antigen 3 (MAGE-3)–derived CD4+-
CD8+ T-cell peptide epitopes in SC-immunized mice, have been
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killing MAGE-3–speciﬁc tumor cells and causing regression of
the growth of mouse forestomach carcinoma cell line.21
γ-PGA
Mice immunized with γ-hPGA NPs carrying the
listerolysin296–307 CD8
+ T-cell peptide epitope have proved to
be protected from a lethal infection with Listeria monocytogenes
without the need of additional adjuvant.42 γ-hPGA NPs
entrapping an endoplasmic reticulum transport system contain-
ing an endoplasmic reticulum–insertion signal sequence–
conjugated antigenic peptide (Tax38–46 peptide derived from
human T-cell leukemia virus type 1 and gp10025–35 human
melanoma peptide) markedly ampliﬁed and activated cytotoxic
T cells and IFN-γ–secreting cells speciﬁc for the antigen in SC-
immunized mice.43 Additionally, in a murine model of tumor
metastasis, intraperitoneal (IP) vaccination with γ-hPGA NPs
loaded with the tumor-associated antigen (TAA)–derived
peptide, the ephrin type A receptor 2 (EphA2), have been
reported to exhibit an enhanced EphA2-speciﬁc CD8+ T-cell
activation and have demonstrated an antitumor effect by eliciting
immunity equivalent to that of the antigen administered with
complete Freund's adjuvant.44
PLGA
PLGA NPs encapsulating both the tyrosinase-related protein 2
(TRP-2)180–188 (self-TAA peptide) and 7-acyl lipid A (TLR4
agonist) have been shown to induce therapeutic immunity against
highly aggressive B16 melanoma in SC-immunized mice,
breaking immunotolerance to cancer-associated self-antigens and
leading to tumor growth control through the induction of TRP-2–
speciﬁc cytotoxic T cells. Activated TRP-2–speciﬁc CD8+ T cells
have been shown to secrete IFN-γ in the lymph nodes and spleens
of the vaccinated mice. Within the tumor microenvironment
there was reversal of the immune-suppressive milieu through
an upregulation of pro-inﬂammatory cytokines (IL-6, IL-12,
IFN-γ, tumor necrosis factor-α) and a downregulation of the
proangiogenic vascular endothelial growth factor.57
Protein-based vaccines
A suitable vaccine must elicit a T-cell response in a
background of many different human leukocyte antigen (HLA)
class I and II alleles. Vaccines providing the immune system with
complete proteins are ideal in contrast to vaccines containing a
single peptide epitope, in that the latter may not contain all
important epitopes suitable for loading onto antigen-presenting
molecules of individuals with different HLA haplotypes.126
Intact recombinant proteins are thus more likely to bear peptide
sequences and to originate peptides that could bind MHC class I
or II molecules of more than one HLA haplotype.
Some examples of polymeric nanogels currently being tested
as potential protein-based vaccine delivery systems are summa-
rized below under the name(s) of the polymer(s) chieﬂy
modiﬁed: mannan and pullulan; chitosan and derivatives; γ-
PGA; PLA and PLGA; PCL; PMMA.
Mannan and pullulan
Cholesterol-bearing mannan or pullulan (CHM or CHP) in
complex with human epidermal growth factor receptor 2 (HER2)oncoprotein has been successfully used to induce CD8+
cytotoxic T cells against HER2+ tumors. Mice immunized SC
with CHM-HER2 or CHP-HER2 before or early after tumor
challenge successfully rejected HER2-transfected tumors.130,131
In addition, vaccination with CHM-HER2 complexes led to a
strongly enhanced production of IgG against HER2.130 In
another study, CHP was used in combination with New York-
esophagus-1 (NY-ESO-1) protein (CHP–NY-ESO-1) to pulse
DCs, which efﬁciently activated both CD4+ and CD8+ T cells in
vitro.123 This further indicated the suitability of CHP for use as a
vaccine delivery system in cancer therapy. The evaluation of
CHP-based protein vaccine in clinical trials yielded encouraging
results. In a phase I clinical trial conducted in HER2-expressing
cancer patients, the CHP-HER2 complex vaccine, administered
SC, proved to be safe and to induce HER2-speciﬁc CD8+ and/or
CD4+ T-cell immune responses16; in a second clinical trial with
this vaccine, it was further shown to induce a HER2-speciﬁc
humoral immune response that was increased by co-administra-
tion of granulocyte-macrophage colony-stimulating factor.17
Despite the CHP-HER2 formulation's effectiveness in raising
the production of antibodies speciﬁc for the immunogen used,
these antibodies were not able to bind to or promote the lysis of
HER2-expressing tumor cells. Their usefulness, however, could
reside in their usage as surrogate markers for the T cell–mediated
immune response.17 In a phase I clinical trial, CHP–NY-ESO-1
vaccine elicited potent humoral19 and increased CD4+ and CD8+
T-cell responses in immunized cancer patients.20 Despite the
NY-ESO-1–speciﬁc immunity induced in cancer patients by
CHP–NY-ESO-1, tumor growth was nevertheless observed
upon vaccination.132 Combined CHP–NY-ESO-1 and CHP-
HER2 vaccines administered SC to esophageal cancer patients
elicited limited mild adverse events.18 Targeting multiple tumor
antigens proved to be feasible, without antigenic interactions.
The combination vaccine elicited a response to NY-ESO-1
comparable to that obtained with the single vaccine, while
inducing a lower antibody production speciﬁc for HER2.18
Although the induction of antigen-speciﬁc T-cell responses upon
vaccination is a promising result, further studies will be
necessary to fully understand the true potential or effectiveness
of CHP- and CHM-based cancer vaccination. The identiﬁcation
of immunological biomarkers that could allow a more accurate
evaluation of the clinical response to cancer immunotherapeutic
approaches133 will certainly be useful in this regard.
Chitosan and derivatives
Chitosan-based vaccines have shown superb effectiveness in
preclinical models and promising results in clinical trials.
Nevertheless, further optimizations for these systems will be
necessary for clinical approval.109,134 Formulations of superox-
ide dismutase B1 in chitosan NPs administered SC to mice have
been reported to increase the NPs' immunogenicity toward cell-
mediated immunity (Th1 cells, IgG2a) and to be effective against
Leishmania.26 Hydrophobic NPs (PLA or PLGA) coated with
hydrophilic polymers (PEG or chitosan) and NPs made solely of
hydrophilic polymers have proved suitable to deliver proteins
across the nasal and intestinal mucosae,23 as exempliﬁed by
chitosan NPs loaded with TT, which elicited high and long-
lasting IgG22,23 and secretory immunoglobulin A (sIgA)
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nant HBsAg with the alginate-coated chitosan NPs in IN-
immunized mice proved to be able to elicit a mucosal but not a
systemic humoral immune response. However, antigen-speciﬁc
systemic antibodies of Th1-associated isotypes were detected
when NPs were used together with CpG.25 In another study the
recombinant HBsAg-loaded chitosan NPs induced levels of IgG
speciﬁc to HBsAg as much as nine times that of the alum-
adsorbed vaccine in IM-immunized mice.24 Colloidal polyelec-
trolyte complexes, free of chemical cross-linkers and surfactants,
were obtained by chitosan and dextran sulfate macromolecular
assembly and loaded with HIV-1 p24. In the murine model, upon
SC vaccination with these NPs, a strong, speciﬁc p24-speciﬁc
antibody production and cytokine release suggested that both
arms of immunity have been stimulated, although the immune
response could be Th2 biased.
135
TMC NPs carrying monovalent inﬂuenza A subunit H3N2
have been described to signiﬁcantly enhance systemic IgG and
local sIgA immune responses in mice (administered IM or IN),
compared to soluble inﬂuenza vaccine.39 Urease, a target antigen
used in vaccination against Helicobacter pylori infection, loaded
into TMC NPs, have elicited speciﬁc IgG and sIgA responses
when orally administered, but only IgG in SC-immunized mice.41
TMC NPs have induced humoral and mucosal immune responses
against recombinant HBsAg in IN-immunized mice.38 Another
study reported that TMC-based formulations containing either
OVA or diphtheria toxoid were able to elicit high titers of IgG
speciﬁc for both antigens, in intradermally (ID) immunized
mice.33 TMC-OVA conjugate (OVA covalently linked to TMC)
caused higher OVA-speciﬁc IgG levels than plain OVA or a
physical mixture of TMC and OVA in IM-immunized mice, and
slightly elevated levels when compared to those achieved with
TMC-OVA NPs obtained by ionic complexation.34 Intraduodenal
vaccination of mice with OVA-loaded chitosan and TMC NPs led
to signiﬁcantly higher antibody response than immunization with
OVA alone. TMC NPs could induce OVA-speciﬁc antibodies
after only a priming dose. TMC NPs but not chitosan or PLGA
NPs had an intrinsic adjuvant effect on DCs.32 Among similar-
size OVA-loaded PLGA, TMC, and TMC-coated PLGA (PLGA-
TMC) NPs, only mucoadhesive TMC was able to increase the
nasal residence time of OVA compared to OVA alone. All
nanosystems administered IM induced higher IgG titers than
OVA alone—PLGA and TMC being superior to PLGA-TMC.
Slow antigen-releasing PLGA and PLGA-TMC NPs did not
induce detectable antibody titers, whereas positively charged, fast
antigen-releasing TMC NPs led to high sIgA and serum antibody
titers in IN-immunized mice. Therefore, particle charge and
antigen release pattern of OVA-loaded NPs must be adapted to
the intended route of administration.35 Additionally, covalently
stabilized TMC–hyaluronic acid NPs loaded with OVA have
shown adequate loading efﬁciency, somewhat greater particle
integrity, and enhanced adjuvanticity as evidenced by higher IgG
titers, as compared with nonstabilized particles in ID- and IN-
immunized mice.37
γ-PGA
The potential of using self-assembled γ-hPGA NPs in
triggering murine immunity has been demonstrated for severalprotein antigens, such as HIV-1 p24,47 HIV-1 gp120,46,99
inﬂuenza hemagglutinin,48,49 and OVA.42,45,111 In macaques
(IN and SC), HIV-1 gp120–carrying γ-hPGA NPs have shown
great potential for the induction of speciﬁc cellular and humoral
immunity. However, themacaques intravenously (IV) challenged
with simian and human immunodeﬁciency chimeric virus
(SHIV)-KU-2 have presented an increased viral load when
immunized with those NPs. Thus, the induced immune response
was not effective for protection but actually enhanced the
infection in rhesus macaques.136 Furthermore, γ-hPGA NPs
proved to be promising adjuvants and allergen-delivery systems
for allergen-speciﬁc immunotherapy; human monocyte-derived
DCs from allergic subjects stimulated in vitro with a mixture of γ-
hPGA NPs and extract of grass pollen allergen Phleum pratense
increased allergen-speciﬁc IL-10 production and proliferation of
autologous CD4+ memory T cells.72 More recently, OVA–
benzalkonium chloride–γ-PGA complex administered SC to
mice has been described to induce IgG1−Th2-type−IgG2a, and
IgG3−Th1-type antibody isotypes, indicating the ability of this
complex to induce humoral and cellular responses. This complex
was able to inhibit the growth of OVA-expressing tumor cell line
E.G7 and caused complete tumor rejection.137
PLA and PLGA
PLA NPs coated with HIV-1 p24 have been described to
induce enhanced cellular and humoral immune responses in
mice, rabbits, and macaques immunized by the SC route.53 Co-
adsorption of HIV-1 p24 and gp120 to these NPs preserved their
antigenicity and immunogenicity.54 In another study in which
mice were also immunized SC, OVA and poly(uridylic acid)
(poly-U, a TLR7/8 agonist), co-encapsulated in PLA NPs,
increased the speciﬁc humoral immune response and the levels
of IFN-γ–secreting T cells.52
PLGA NPs have been reported as effective vehicles for
sustained and targeted antigen delivery to APCs by efﬁciently
trafﬁcking through local lymphoid tissues.138,139 Co-delivery of
hepatitis B core antigen (HBcAg) and monophosphoryl lipid A
in PLGA NPs promoted HBcAg-speciﬁc Th1 cellular immune
response with IFN-γ production in a murine model immunized
SC.64 Encapsulated West Nile virus envelope protein antigen
conferred host protection in a murine model of viral
encephalitis.140 In another study, PLGA particulate delivery of
OVA and 7-acyl lipid A to DCs led to an increased antigen-
speciﬁc CD8+ and CD4+ T cell–mediated response.58 The
expanded T cells were capable of cytokine secretion and
displayed an activation and memory surface phenotype.58 Oral
administration to mice of OVA and monophosphoryl lipid A co-
delivered in PLGA NPs proved to induce both systemic and
mucosal immune responses.59 LPS-modiﬁed PLGA NPs, in SC-
immunized mice were able to effectively enter APCs, eliciting
both humoral and cellular immunity against encapsulated OVA,
without toxicity, therefore proving to be an effective vaccine
vector through both TLR and inﬂammasome activation.140
DEC-205–targeted OVA-loaded PLGA NPs have been demon-
strated to induce DCs to produce IL-10, with levels correlating
with the amount of DEC-205–speciﬁc monoclonal antibodies
conjugated on the particle surface, both in vitro and in IP-
immunized mice.141 This delivery system induced DCs and T
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anti-inﬂammatory (IL-10) cytokines. The DEC-205–associated
pathway elicited the DC production of IL-10 and T-cell
production of IL-10 and IL-5 without impeding IL-12–mediated
DC priming of a Th1-type response characterized by IFN-γ
production, as a result of the PLGA component. Multivalent
cross-linking of the DEC-205 receptors was required for the
response and was associated with the upregulation of the
scavenger receptor CD36 on the DCs.141
PCL
PCL NPs modiﬁed by different adjuvants (mucoadhesive
polymers alginate or glycol chitosan; and absorption enhancers
spermine or oleic acid), with Streptococcus equi equi (S. equi)
surface proteins adsorbed or encapsulated, have been shown to
induce signiﬁcantly higher speciﬁc systemic and mucosal immune
responses to S. equi antigens in IN-immunized mice.67 The
inclusion of cholera toxin B subunit in the formulations further
activated the pathways leading toTh1 andTh2 cells differentiation.
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PMMA
Vaccine formulations composed of HIV-1 Tat protein and
anionic surfactant–free polymeric core-shell NPs and MPs with
an inner core constituted by PMMA and a hydrophilic outer shell
composed of a hydrosoluble co-polymer (Eudragit L100-55)
have been demonstrated to induce robust and long-lasting
cellular and humoral immune responses in mice after systemic
and/or mucosal immunization.71
DNA-based vaccines
In DNA-based vaccines, the peptide/protein targets of
immune response are encoded in DNA and produced within
the body's own cells, which can mimic actual infection more
closely than injection of traditional nonreplicating vaccines.142
The DNA vector is made of a bacterial-derived plasmid equipped
with eukaryotic or viral promoter–enhancer transcription
elements and a gene encoding the antigen of interest followed
by a transcript termination–polyadenylation sequence.143
DNA-based vaccines accumulate desirable qualities, such as
immunogenicity (expression of multiple antigens or epitopes in a
single vector inducing antigen-speciﬁc humoral and cellular
immune responses), safety (low cytotoxicity and reduced
immunogenic reactions), versatility (i.e., vaccine targets can be
simply, rapidly, and economically changed by selecting the
appropriate sequence of the plasmid DNA), easy to scale up and
manufacture (low cost and reproducible large-scale production
and isolation), stability (long shelf-life), and mobility (ease of
storage and transport, not likely to require a cold chain).82,143,144
The principal drawbacks lie in the challenging intracellular
delivery of DNA in the appropriate cell type (APCs or a bystander
cell) and the low levels of transfection that may consequently limit
the immune response.82 The approach of co-inoculating plasmids
encoding different cytokines, co-stimulatory factors, or other
fusion constructs to enhance or modify the immune response
generated by the vaccine plasmid has been used successfully.144
Different polymers have been extensively studied as nonviral
DNA carriers for vaccine delivery,120 and some examples are
summarized below.Chitosan
Chitosan NPs containing a cocktail of DNA encoding nine
immunogenic antigens of respiratory syncytial virus have been
demonstrated to elevate the production of IFN-γ in the lungs,
and to induce high levels of IgG and sIgA and cytotoxic T cells
with antiviral action in a mice model.31 Plasmid DNA expressing
different Mycobacterium tuberculosis epitopes loaded on
chitosan NPs, when administered by the pulmonary route in
mice, proved to increase IFN-γ secretion from T cells.29
Chitosan NPs loaded with DNA encoding VP1, a major
structural protein of coxsackievirus B3, induced high levels of
IgG and sIgA and a strong cytotoxic T-cell response that
effectively eliminated coxsackievirus B3 viruses in IN-immu-
nized mice.30 The chitosan complexes with plasmid DNA
encoding HBcAg in IM-immunized mice displayed stronger
immunogenicity than naked DNA vaccines, with a higher level
of speciﬁc antibody, elevated IFN-γ secretion, and increased
speciﬁc cell lysis.118 Plasmid DNA encoding HBsAg loaded on
chitosan NPs induced humoral, both systemic and mucosal, and
cellular immune responses in IN-immunized mice.28 Low-
molecular-weight chitosan, although having lower binding
afﬁnity to plasmid DNA encoding human cholesteryl ester
transfer protein C-terminal fragment, mediated higher transfec-
tion efﬁciency, elicited signiﬁcant systemic immune response,
modulated plasma lipoprotein proﬁle and attenuated the
progression of atherosclerosis in IN-immunized rabbits.145
Oral delivery of chitosan-DNA vaccine encoding mite dust
allergen from Dermatophagoides pteronyssinus generated high
gene expression levels in mice, and preferentially activated a
speciﬁc Th1 immune response, thus preventing subsequent
sensitization toward Th2 cell–regulated speciﬁc IgE response.
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γ-PGA
DNA vaccination with PEI/γ-PGA NPs loaded with a
plasmid encoding Plasmodium yoelii merozoite surface protein
1 C terminus, administered IV in mice, has been shown to
generate an antigen-speciﬁc IgG response dominated by IgG1
and IgG2b and to induce weak Th1 (IFN-γ and IL-12 p40) and
strong Th2 (IL-4) cytokines responses.
50 In another study, the
same complex when administered IV and IP, provided complete
protection against lethal challenge with a signiﬁcant increase in
levels of immunoglobulins and Th1 and Th2 cytokines, but in the
group vaccinated SC, only half of mice were protected and
marginal levels of speciﬁc antibody were measured.51
PLA and PLGA
A single dose of plasmid DNA encoding β-galactosidase
encapsulated in PLA-PEG NPs induced a signiﬁcant systemic
antibody response to the encoded protein in IN-immunized
mice.78 Multifunctional core-shell polymeric NPs, comprising a
hydrophobic PLGA core loaded with ﬂuorescent quantum dots
and a reporter gene electrostatically adsorbed onto the positively
charged glycol chitosan shell, could be delivered transdermally
in a mouse model via gene gun bombardment. The loaded DNA
was intracellularly released via a pH-mediated mechanism,
directly into epidermal Langerhans cells, which then migrated
and expressed the encoded gene products in the skin-draining
lymph nodes.147
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M. tuberculosis latency antigen Rv1733c, when applied to the
lungs, increased T-cell proliferation and IFN-γ production more
potently than the same formulations given IM to mice. The
strongest immunogenicity was obtained by pulmonary priming
with NPs-adsorbed Rv1733c DNA followed by boosting with
Rv1733c protein.65
RNA-based vaccines
Signiﬁcant challenges continue with respect to delivery of
RNA-based NPs.148 The RNA-based vaccines, in contrast to
those of DNA, offer a simpler delivery directed to the cytoplasm,
thus bypassing dependence on cellular transcription machinery
and transport of nucleic acids to and from the nucleus, excluding
any potential for integration into host chromosomes. Neverthe-
less, RNA is relatively labile and expensive to manufacture at a
commercial scale.
Efﬁcient transfection of DCs with messenger RNA (mRNA)
expressing TAA, followed by vaccination with the RNA-pulsed
DCs, has shown promising results in murine models and recently
in humans. In this context, prior identiﬁcation and characteriza-
tion of individual gene sequences encoding the TAA seems to be
nonessential, as preparations of total mRNA isolated directly
from tumors may also be used.149
The mRNA-based vaccines in vivo may have to deal with
potency issues related to limited transfected mRNA copies into
each cell and insufﬁcient levels of expressed protein antigen to
stimulate the desirable immune response. A smart strategy to
increase the intracellular levels of mRNA comprises the
incorporation of replication elements derived from RNA viruses
(alphaviruses, ﬂaviviruses, and picornaviruses), which together
program the cytoplasmic self-ampliﬁcation of RNA within
transfected cells. To avoid the production of any detrimental
infectious virus, essential virus genes such as those encoding the
structural “coat” proteins are excluded, originating modiﬁed
RNA vaccine vectors, termed “replicons.”149
Biodegradable core-shell NPs—comprising a pH-responsive
poly(β-amino ester) core, selected to promote endosome
disruption, enveloped by a phospholipid bilayer shell to reduce
the polycation core toxicity—were designed for in vivo mRNA
delivery with possible usage in noninvasive delivery of mRNA-
based vaccines. These NPs loaded with luciferase-encoding
mRNA led to statistically higher expression of the reporter
protein luciferase than in the naked-mRNA treatment group,
when administered IN to mice.150Concluding remarks and future perspectives
Polymeric nanogels effectively perform as targeted carriers
protecting vaccine antigens from degradation in vivo. Following
internalization of the biomaterial vehicles by APCs, the loaded
antigens are released intracellularly and enter MHC class II– and
class I–dependent antigen presentation pathways, and, therefore,
can induce both CD4+ and CD8+ T cell–mediated immunity.
Moreover, the surface of the biomaterial vehicle can be
conjugated with antibodies or other speciﬁc ligands to improve
tissue, cellular, or subcellular targeting speciﬁcity, steer speciﬁcimmune response by improving the efﬁcacy achieved at a much
lower antigen dose, and/or reduce inﬂammatory side effects
associated with some “danger signals.” Biomaterials themselves
can function as synthetic adjuvants, which can also be
conjugated with immunostimulants that activate APCs and
induce subsequent T-cell immunity. Advantages in the usage of
polymeric nanogels as antigen delivery systems comprise their
simplicity of formulation, loading capacity, stability of the
resulting dispersifon, nontoxicity, lower cost, and easiness of
manufacture and scale-up.
Although peptide- and RNA-based vaccines are currently less
developed than DNA- or protein-based vaccines, major advances
in these newer vaccines can be expected in the near future. A
comprehensive evaluation of all of the latest vaccination
concepts, together with a better understanding of disease
pathology, advances in biomaterials science and technology,
and regulated systematic experiments, will provide more
delivery systems (proven safe, effective, and targeted) that
actually advance preventive and therapeutic vaccines to the next
level, achieving a major goal in global public health.
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